本帖最后由 老马 于 2012-1-13 21:20 编辑 ; N" W6 Y8 m8 n8 V4 a
# l; W- H, U0 w0 `. {* t
爱必妥和阿瓦斯丁的比较8 c6 U, K" s' l& I$ Y, ^% ^
, Q, d( s. }; p+ L+ l7 r! P# J5 a
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/ o) c8 T5 S0 `( m
) k8 {! j) _# F0 r$ w* ^# d
! _& {0 d3 l; y" Q) z5 Y2 ~0 {" Ghttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/, G/ u+ ?3 o, U0 T3 t; T! }) d" ^
==================================================
, o0 e( d; t! a3 H" Y: |% rOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)9 B" ` A, c; V% O
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
+ C4 S( }, T. CResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
' X: S9 u% T0 V8 N$ T
|